Insulin costs have been steadily increasing, forcing many people with diabetes to choose between purchasing this live-sustaining medication or paying for other necessities. In May 2018, the ADA’s Insulin Access and Affordability Working Group released findings from their research and stakeholder discussions. As follow-up to the Working Group’s work, the ADA has released a Public Policy Statement with an array of short-term and long-term recommendations to help shed additional light on the issue, to combat increasing insulin costs, and to improve affordable access to medications, including:
- Streamlining the biosimilar approval process
- Increasing pricing transparency throughout the insulin supply chain
- Lowering or removing patient cost-sharing for insulin
- Increasing access to health care coverage for all people with diabetes.